ELAB — PMGC Holdings Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1840563 ·
Last close
$1.46
Market Cap
$6.63M
52W High
$14.00
52W Low
$1.34
ADV30
2,056,200
Next earnings
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 681,994 230,474 -3,320,057 -4,967,259 26,033,318 14,354,374 13,426,865
Dec 2025 304,136 107,284 -2,410,864 -2,982,683 12,868,473 5,402,333 5,031,111
Sep 2025 285,948 78,030 -2,194,727 -2,594,320 14,938,018 7,700,562 6,447,363
Jun 2025 0 -1,014,401 -562,355 9,375,476 5,682,628 326,301

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,566,060
Investing CF
$-5,033,444
Financing CF
$21,586,459
CapEx
$-1,105,342
Dividends Paid
Buybacks
$0
EPS Diluted TTM
$-414.99
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-25,984,699
Inventory
$253,558
Receivables
$542,715
ST Investments
$733,405
EBIT TTM
$-10,434,391
Pretax Income TTM
$-11,155,717
Interest Exp TTM
$721,326
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,272,078
EBITDA
$-9,028,514
Free Cash Flow
$-2,403,837
Enterprise Value
$-618,966
Total Cash
$15,210,586
Total Debt
$7,957,106
Shares Out
4,543,751
Trailing EPS
$-150.06
Book Value
$6.51
ROE
-107.9%
ROA
-33.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 590,084 -6,821,330 -7,747,813 12,868,473 5,031,111 -5,933,881
Dec 2024 0 -3,657,720 -6,245,737 8,993,165 2,333,601 -5,486,980
Dec 2023 0 -1,134,828 -4,301,517 5,189,918 1,362,842 -4,556,811
Dec 2022 766,277 -1,788,292 -1,800,268 1,892,183 760,873 -1,585,876

Peers — same industry

TickerNameMarket CapLastDaily %
SNGX SOLIGENIX, INC. $6.67M $0.45
ACXP Acurx Pharmaceuticals, Inc. $6.75M $1.57
SILO Silo Pharma, Inc. $6.86M $6.33
CANF Can-Fite BioPharma Ltd. $6.41M $2.99
CNSP CNS Pharmaceuticals, Inc. $6.93M $4.74

News headlines (Yahoo Finance, 1h cache)

PMGC Holdings Highlights Advanced Precision Manufacturing Capabilities Supporting Space Exploration Supply Chains
2026-06-10 11:31 · Yahoo
NorthStrive Defense Tech Executes Binding Agreement to Acquire Exclusive License to Patented Multi-Domain Drone Payload Technology for Defense, Aerospace and Maritime Applications
2026-06-08 11:31 · Yahoo
PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets
2026-06-01 11:31 · Yahoo
GB Capital Ltd. Co-Advises on the Acquisition of A&B Aerospace Inc.
2026-05-18 13:00 · Yahoo
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q1 2026 Results and Files Form 10-Q; Total Assets Reach Over $26.0 Million, Up 102% from Year-End 2025 and 193% Year-over-Year
2026-05-15 11:02 · Yahoo
PMGC Grabs Precision Parts Maker Serving Boeing, Honeywell
2026-05-13 12:42 · Yahoo
PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc.
2026-05-13 08:03 · Yahoo
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atr
2026-04-28 20:01 · Yahoo
NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
2026-04-28 11:30 · Yahoo
NorthStrive Defense Tech Acquires Patented GPS-Denied Autonomous Drone Navigation Technology Option, Built for Defense and Counter-Unmanned Aircraft Systems
2026-04-23 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.